Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy

Islet Transplantation Clinical Trial

Official title: Clinical Islet Transplantation With Apheresis, Isolation and Reintroduction of Recipient Regulatory T Cells or Administration of Deceased Donor Vertebral Bone Marrow in Type 1 Diabetes

Status Not yet recruiting

Clinical Trial Summary

The goal of this clinical trial is to learn if patients who have brittle type 1 diabetes receiving an islet transplantation will have better control of their sugars if they also receive one of 2 types of immune cells along with the islet transplant. The participants will receive either their own immune cells, called regulatory T cells, or immune cells from the bone marrow of the islet donor.

Clinical Trial Description

Islet transplantation success remains limited by the immediate loss of islet after transplantation, rejection, and side effect from immunosuppression. Preclinical animal models provide evidence that donor bone marrow cells OR regulatory T cells infused at the time of islet transplantation can improve the survival of islets after transplantation and reduce the need for immunosuppression. The purpose of this study is to evaluate the feasibility and safety of combining an islet transplant with the recipient's Tregs OR deceased donor bone marrow cells in patients with brittle type 1 diabetes. ;

Related Conditions & MeSH terms

• Death
• Islet Transplantation

• NCT number: NCT05973734
• Study type: Interventional
• Source: Stanford University
• Contact: Kevin Ly, BS
• Phone: 650-497-6057
• Email: kevinly@stanford.edu
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: October 1, 2023
• Completion date: May 2028